←
Nan Li1,056 posts
Nan Li avatar

Nan Li

@nanli

Founder @_DimensionCap

◷ Joined March 2009▧ 55 Photos and videos
Nan Li avatar
Nan Li@nanli·Jul 21

Thrilled to announce Dimension III, a fresh $800M fund which takes the firm up to $1.6B AUM. Even since we launched the firm a few years ago, the overlapping exponential curves of science, AI, infrastructure, and hardware have continued to scale at staggering rates. We are more certain than ever that a research-led, long-term oriented investment practice is the right capital partner to ambitious founders in this era. If you are building something technically ambitious and possibly a little crazy, you are in good company here. While the fund, our team, and our ambitions continue to grow, we remain steadfast on our mission to partner with founders building at the frontiers of science and compute. Excited for the future ahead, let’s go build it!

DIMENSION @_DimensionCap Jul 21 Article Dimension III: a $800M fund to invest across the frontiers of science and compute Don't be encumbered by history - go off and do something wonderful (Robert Noyce) To our current and future Founders: Today we write to announce the launch of Dimension III, a $800M fund to invest

changhiskhan avatar
⟳ Nan Li retweeted
changhiskhan@changhiskhan·20h

Our customers are building AI that generates video, drives cars, and helps robots understand the world. We just raised a $57.5M Series B to help them do that faster, led by @BessemerVP and @iendeavors . Years ago, I helped write pandas for a world where data just meant numbers of strings. Later, running ML engineering at Tubi, I saw the limits of that world up close. The data that matters for AI now is video, images and sensor logs, and the tools we all grew up with were never built for it. @eddyxu and I started @lancedb because we lived that problem and couldn't stop thinking about it. Nowhere is the shift clearer right now than in physical AI. Robots and autonomous vehicles learn from enormous volumes of video and sensor data, and the teams building them were losing weeks to data wrangling before every training run. Teams like @runwayml and @nvidia Cosmos curate millions of hours of video using Lance and is now training directly from it. Earlier this month at Reverie (reveriesummit.com), our first summit, the topic robotics and autonomy teams kept coming back to was the data flywheel, and how to make it spin faster. That is what this round is for. We're building the multimodal lakehouse so that a researcher's only limit is their ideas, not their infrastructure. Since our Series A, revenue has grown more than 10x year over year, and open source downloads have grown 6x in the past year. More importantly, we've a team that I am proud to be part of every single day, customers who trusted us with their hardest workloads, and a community of contributors and maintainers who make the project better every day. To our investors: thank you. @BessemerVP and @iendeavors for leading, and @Theoryvc, @_DimensionCap , @swift_vc , @CRV and @ycombinator for backing us again and again. You believed in what this could become, and we don't take it for granted. We're still in the early innings. If you want to build the data foundation for the next decade of AI, we're hiring. lancedb.com/blog/lancedb-ser…

2:53
Nikhil Namburi avatar
⟳ Nan Li retweeted
Nikhil Namburi@nikhilvnamburi·19h

The world is multi-modal. Your data warehouse should be too! I’ve been a happy user of @lancedb since 2024, it’s a magical experience. Turns out your favorite AI labs agree :) Honored to partner with @changhiskhan @eddyxu

The next generation of models needs a data stack built for AI. We just raised a $57.5M Series B to help researchers turn petabytes of video, images, and audio into better models, faster. Read the announcement: lancedb.com/blog/lancedb-ser…

2:53
Nan Li avatar
Nan Li@nanli·19h

Excited to announce @_DimensionCap’s partnership with @changhiskhan, @eddyxu and the team at @lancedb! Lance has built the leading database for large scale, multimodal data. This data workload is increasingly common in large scale AI training and some of the top research groups working on frontier models, world models, robotics, etc have switched over to LanceDB. Excited for the journey ahead, more soon!

The next generation of models needs a data stack built for AI. We just raised a $57.5M Series B to help researchers turn petabytes of video, images, and audio into better models, faster. Read the announcement: lancedb.com/blog/lancedb-ser…

2:53
Nan Li avatar
Nan Li@nanli·Nov 11

Congrats on the firm launch Sahir!!

So excited to share more about what I have been up to. @ProximalVC is a first check fund that loves to partner with founders before incorporation to support ideation and initial GTM strategy. If you’re building the systems that make discovery smarter, trials faster, manufacturing more resilient, supply chains more transparent or commercial execution more precise - please reach out!

Nan Li avatar
Nan Li@nanli·Nov 6

AI will not solve everything instantly, but it's tough to be on the record betting against technology... Credit to visionaries like @RecursiveChris who have been building the future for a long time.

At the risk of a confusing positive-double-negative, I’m so aligned with @SimonDBarnett. It appears Vertex hasn’t even made it to the starting line in the AI race. Their chairman seems to believe that because they ran AI “through a dataset of 10,000 compounds” and didn’t get a medicine out the other side, it means AI doesn’t work. There are many dozens of AI-discovered drugs in the clinic - some in or approaching phase 3. Up from zero roughly 10 years ago. The first will get approved, then ten, then hundreds. That’s what exponential curves look like. There can be plenty of debate around when we will hit 100 AI medicines approved, and it’s easy to be off by years (I originally thought we’d be there around now), but believing today that it isn’t going to happen in the coming years is the equivalent of being an ostrich with its head underground as the lions arrive.

Chris Gibson avatar
⟳ Nan Li retweeted
Chris Gibson@RecursiveChris·Nov 6

At the risk of a confusing positive-double-negative, I’m so aligned with @SimonDBarnett. It appears Vertex hasn’t even made it to the starting line in the AI race. Their chairman seems to believe that because they ran AI “through a dataset of 10,000 compounds” and didn’t get a medicine out the other side, it means AI doesn’t work. There are many dozens of AI-discovered drugs in the clinic - some in or approaching phase 3. Up from zero roughly 10 years ago. The first will get approved, then ten, then hundreds. That’s what exponential curves look like. There can be plenty of debate around when we will hit 100 AI medicines approved, and it’s easy to be off by years (I originally thought we’d be there around now), but believing today that it isn’t going to happen in the coming years is the equivalent of being an ostrich with its head underground as the lions arrive.

Zavain Dar avatar
⟳ Nan Li retweeted
Zavain Dar@zavaindar·Nov 5

Deals from Chai, just this year: - lilly - pfizer - bms - argenx - gsk - novartis - roche breakthrough magical technology is breaking the laws of biopharma business physics

Today we’re launching @chaidiscovery, led by @joshim5 & his polymathic world class cofounders. We’re also open sourcing Chai-1: a state of the art frontier model for biomolecular interactions. @_DimensionCap has co-led the founding round alongside Thrive & OpenAI

Post attachment
Joshua Meier avatar
⟳ Nan Li retweeted
Joshua Meier@joshim5·Nov 5

Today we’re announcing a collaboration with @Roche, a leader in AI-driven drug discovery. Roche will apply @chaidiscovery's platform to help accelerate discovery programs across a number of targets in its therapeutic areas.

0:09
Bowen Jing avatar
⟳ Nan Li retweeted
Bowen Jing@bjing2016·Oct 28

Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude. At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells. Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI. We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force. Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.

0:15
Frank Gao avatar
⟳ Nan Li retweeted
Frank Gao@ChemVagabond·Oct 28

So pumped to share our third volume of the @_DimensionCap Research magazine! These articles were enjoyable to write alongside my research colleagues @SimonDBarnett and @bauer_lesavage In this volume, we dive deep into the foundations and applications of AI models, from pre-training, post-training, and agentic use to the emerging bio data market. This volume also features my first research article on applying autoresearch for training machine learning models to predict protein thermostability. I assessed how frontier models approach hyperparameter tuning and discussed how such an approach can be synergistic with traditional Bayesian optimization sweeping and expert-guided search. Since the article’s publication in April, we have seen a tremendous amount of progress in recursive self-improvement for closed-loop scientific discovery, and this is only the beginning! Our goal here is to present these broad topics in a rigorous yet accessible manner for everyone, no matter if you’re a frontier ML researcher or a weekend biotech warrior. We very much hope you enjoy!

Post attachmentPost attachment
Bauer LeSavage avatar
⟳ Nan Li retweeted
Bauer LeSavage@bauer_lesavage·Oct 28

Excited to share our third volume of the @_DimensionCap Research magazine! These articles were a blast to write with my research colleagues @SimonDBarnett and @ChemVagabond, and I feel so lucky to get to brainstorm, debate, learn, and write about these topics alongside them both on a daily basis. You’ll probably notice a theme to a lot of these articles that we have written throughout 2026: the chronicles of us diving head first into AI model training, the data needed to feed them, and emergent applications of training at the frontier. One of my favorite articles I wrote this year was centered around the bio data market and why biological training data has such unique considerations compared to text data. Since I published this one back in June, the demand for high-quality, therapeutic-relevant bio data has become even more obvious, and I don’t see this demand slowing down. The impact that AI is and is going to have in bio is becoming increasingly apparent every day, and we can’t get there without the right datasets. Our goal here is to make these topics accessible and interesting to all, no matter if you’re a frontier ML researcher doing this work daily or brand new to the space and just trying to get a sense of it all. We very much hope you enjoy!

Post attachmentPost attachment
Simon Barnett avatar
⟳ Nan Li retweeted
Simon Barnett@SimonDBarnett·Oct 28

That's a wrap! Today, we're (@_DimensionCap) releasing the third volume of our Research Magazine. Before anything else, I want to shout out my tremendous research colleagues Bauer (@bauer_lesavage) and Frank (@ChemVagabond), who were both core contributors to this volume. We're also releasing a digital version: dimensioncap.com/research-ma… ~~~ Compared to previous magazines, our third work is more heavily focused on machine learning. That's by design. Dimension invests in all companies, small and large, spanning the continuum from compute to the life sciences. At our core, we love technical teams working on the hardest, most important problems. That means data center infrastructure, new networking protocols, new silicon, inference optimization, physical AI, lean/tech-enabled biotechs, data generation, and more. As such, we challenged ourselves to go deeper into the compute stack than ever before, and how it connects to various branches of science. This magazine is a small sliver of the proverbial 'research exhaust' that our team generates over the course of a few quarters. ~~~ One piece I want to highlight is Without Form and Void, which was my attempt at unifying my background in fluid mechanics, my admiration of clever inductive biases in ML, and a major industry chokepoint seldom talked about in CS circles, which is bioprocess scaling. It's also the first piece I've tried writing with this much history (back to Galileo). ~~~ We hope you like Vol. 3 and we can't wait to show you all what's in store in Vol. 4!

Post attachmentPost attachment
Nan Li avatar
Nan Li@nanli·Oct 20

Excellent read covering the underlying theme of surface receptor mapping that has been behind recent Pharma success stories. Outside of the tremendous pace of progress in AI, scaled molecular interrogation and experimental precision continue to play a massive role in scientific progress in biotech. Written by the one and only @ChemVagabond!

Over four decades, HER2 went from a marker of poor prognosis to the target of many transformative medicines. Can we make this story repeatable at scale with unprecedented speed?

Andrew Dunn avatar
⟳ Nan Li retweeted
Andrew Dunn@AndrewE_Dunn·Oct 9

At the start of this year, @joshim5 told me 2026 would be the "year of deployment" for @chaidiscovery That wasn't just an aspiration — Chai has now signed its 6th pharma deal in the past 9 months: Lilly Pfizer Novartis argenx BMS and now with GSK: endpoints.news/chai-discover…